Clinical Trial Data
80% of trial participants at 6-month stage following treatment were showing significantly reduced symptoms of anxiety and depression.
80% endorsing moderately or greater increased well-being/life satisfaction.
Estimated that only 33% of depression patients benefit from currently available treatment options.
80% of participants were abstinent in the 6 month follow up, and 73% were biologically confirmed to have quit smoking (Chantix – best in class currently delivers a 35% quit rate).
12 month follow up showed 67% remained abstinent. In 2017, an additional follow up confirmed that 60% remained abstinent.